Navigation Links
Poniard Pharmaceuticals to Present New Data from Phase 2 Clinical Trials of Picoplatin in Multiple Tumor Types at the 45th Annual Meeting of the American Society of Clinical Oncology
Date:5/4/2009

- Progression-Free Survival Data to be Presented for Phase 2 Colorectal and Prostate Trials -

- Company to Hold Investor Event on Sunday, May 31 with Oncology Experts -

SOUTH SAN FRANCISCO, Calif., May 4 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD) today announced that the Company will present new data from two ongoing Phase 2 clinical trials of picoplatin, the Company's lead product candidate, at poster sessions during the 45th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Orlando. The Company will present results of picoplatin plus docetaxel/prednisone in patients with metastatic castration-resistant (hormone-refractory) prostate cancer (CRPC) and picoplatin plus 5-FU/leucovorin in patients with metastatic colorectal cancer (CRC).

Both presentations will include new, recently obtained, efficacy and safety data, including progression-free survival data, not reflected in the abstracts that will be posted on the ASCO Web site on Thursday, May 14 at 6:00 p.m. Eastern Time. The CRC presentation will be followed by an ASCO poster discussion.

Poster presentation details are as follows:

    --  Results of a Phase II study of picoplatin with docetaxel and
        prednisone in first-line treatment of castration-resistant prostate
        cancer
        Abstract #5140
        R. De Jager, L. Roman, N. Lopatkin, P. Karlov, H. Breitz, R. Earhart
        General Poster Session: Sunday, May 31, from 2:00 p.m.-6:00 p.m.
         Eastern Time
        Level 2, West Hall C, Poster #J6

    --  Randomized Phase II study of picoplatin in combination with
        5-fluorouracil and leucovorin (FOLPI) as a neuropathy-sparing
        alternative to modified FOLFOX-6 as first-line therapy for colorectal
        cancer
        Abstract
'/>"/>
SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Poniard Pharmaceuticals to Present Updated Results of Picoplatin Phase 2 Small Cell Lung Cancer Trial at 12th World Conference on Lung Cancer
2. Poniard Pharmaceuticals Announces Updated Results of Picoplatin Phase 2 Trial Demonstrating Survival Benefit in Small Cell Lung Cancer Patients
3. Poniard Pharmaceuticals Receives FDA Fast Track Designation for Picoplatin for Treatment of Small Cell Lung Cancer
4. Poniard Pharmaceuticals Initiates Randomized Phase 2 Trial of Picoplatin for First-Line Treatment of Metastatic Colorectal Cancer
5. Poniard Pharmaceuticals Provides Year-End Clinical Update at 2007 Lazard Capital Markets Healthcare Conference
6. Poniard Pharmaceuticals Announces Picoplatin Safety Data in Colorectal Cancer
7. Poniard Pharmaceuticals Announces Positive First-line Phase 1 Safety and Efficacy Data With Picoplatin in Metastatic Prostate Cancer Patients
8. Poniard Pharmaceuticals Announces Clinical Data From Picoplatin Oral Phase 1 to Be Presented at the American Association of Cancer Research Annual Meeting
9. Poniard Pharmaceuticals Announces Commercial Manufacturing Agreement With W. C. Heraeus GmbH for Picoplatin
10. Poniard Pharmaceuticals Announces Presentation of Clinical Data From Picoplatin Phase 2 Small Cell Lung Cancer Trial to be Presented at 1st IASLC-ESMO European Lung Cancer Conference
11. Poniard Pharmaceuticals Oral Picoplatin Demonstrates Positive Bioavailability in Ongoing Phase 1 Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... Calif. , Aug. 21, 2014  SI-BONE, Inc. ... device company that pioneered the use of the iFuse ... device indicated for fusion of the sacroiliac (SI) joint, ... published an update to its Lumbar Fusion Medical Policy ... joint fusion procedure.  The policy states that the fusion ...
(Date:8/21/2014)... 21, 2014   Auxilium Pharmaceuticals, Inc. ... company, today announced positive results from a randomized, ... (or CCH) for the treatment of edematous fibrosclerotic ... Phase 2a trial, all three doses of CCH ... an improvement in the appearance of cellulite as ...
(Date:8/20/2014)... Md. , Aug. 20, 2014  The ... lauded the latest results achieved by the real-time, ... as the National Precursor Log Exchange (NPLEx), automatically ... officials track down meth offenders and make arrests. ... Indiana blocked the sale ...
Breaking Medicine Technology:SI-BONE, Inc. Announces Positive Coverage Decision by Priority Health 2SI-BONE, Inc. Announces Positive Coverage Decision by Priority Health 3Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 2Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 3Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 4Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 5Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 6Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 7Indiana's Stop-Sale System Achieves Significant Results In Battle Against Meth 2
... 22, 2011 Innovative Dialysis Systems, Inc. announces the ... in and around Los Angeles with more options for ... are located in Northridge, Torrance, Carson, and downtown Los ... Reseda Boulevard, was the first of the new centers ...
... 22, 2011     ... catch up   with   their urban counterparts in adopting technology ...   data spill shows risk of online health records . ... IT and its current challenges? Ambitious national healthcare IT programmes and ...
Cached Medicine Technology:Innovative Dialysis Systems, Inc., Announces Opening of Four New Dialysis Facilities in Southern California 2Innovative Dialysis Systems, Inc., Announces Opening of Four New Dialysis Facilities in Southern California 3Innovations in E-Health & Informatics Europe: The Need for a European EHealth Strategy 2
(Date:8/21/2014)... Ohio (PRWEB) August 21, 2014 August ... he took his own life by hanging, likely due ... Sharry Edwards, the foremost BioAcoustic Vocal Profiling investigator, ... offering novel information concerning Williams’ death; hoping to help ... Several issues relevant to Williams’ suicide were proposed in ...
(Date:8/21/2014)... DoudouneCanadienneGoosePasCher.fr, one of the most popular suppliers ... its new selection of Trillium Parkas for 2014. Moreover, ... these fashionable and comfortable items are available at discounted ... last until September 01. , The CEO says ... Canada Goose Trillium Parkas for new and old ...
(Date:8/21/2014)... Los Angeles, CA (PRWEB) August 21, 2014 The ... over the past two decades, according to new insurance industry studies. ... its pet insurance finder to locate affordable plans from all 50 ... pet who pays more than $50 for a routine visit or ... plan for coverage. Every user of the system will be asked ...
(Date:8/21/2014)... An increasing amount of complaints have been ... tax payment is being returned by their financial institution. ... IRS, “tax@irs.gov”, it’s actually a phishing tactic used to ... , While similar scams have been going on for ... is occurring right now. , First, it’s important ...
(Date:8/21/2014)... finding motivation to exercise is a challenge. Thankfully, there are ... Zombies, Run!one of more than 31,000 health and fitness apps ... of apps that use games to increase physical activity. , ... makers looking to cash in to help people get fit. ... to be seen. , "It,s just been assumed that gamified ...
Breaking Medicine News(10 mins):Health News:Robin Williams: What he could not bear to face 2Health News:Robin Williams: What he could not bear to face 3Health News:Fashionable And Comfortable Canada Goose Trillium Parkas For Sale At DoudouneCanadienneGoosePasCher.fr 2Health News:Pet Insurance Finder for 50 States Launched at Insurance Website Online 2Health News:Beware Of Phony “Tax Payment Rejected” IRS Emails 2Health News:Playing hunger games: Are gamified health apps putting odds in your favor? 2
... , FRIDAY, March 16 (HealthDay News) -- Women who suffer ... likely to miss days at work, a new Dutch study ... could be insomnia, mood swings, irritability, you may be calling ... Lenox Hill Hospital in New York City. Menopause, which ...
... In Vitro Fertilization [IVF] and the related technologies of assisted ... countries as many as 4% of all babies born are ... no doubt be at least one IVF child. Assisted ... BABY-MAKING: What the New Reproductive Treatments Mean for Families and ...
... (March 16, 2012) An international team of researchers from ... Center in Tampa, Fla., have found that the oral BRAF ... trial offered a high rate of response in patients with ... More than 50 percent of the patients in the trial ...
... By Steven Reinberg HealthDay Reporter , THURSDAY, March ... images and smokers, horror stories will be launched next week, ... The essence of the campaign is having real smokers ... to the agency. For the next 12 weeks, the ads ...
... 16 March 2012: Stroke survivors who like art have ... not, according to new research. Patients who appreciated music, painting ... did not. The research was presented at the ... in Copenhagen, Denmark. , Stroke is the third cause ...
... THURSDAY, March 15 (HealthDay News) -- Politicians may want to ... votes, because people appear to prefer candidates with deep voices, ... and women who listened to recordings of high- and low-pitched ... November." Both the male and female participants "elected" the ...
Cached Medicine News:Health News:Menopause May Cost Women Sick Days 2Health News:Menopause May Cost Women Sick Days 3Health News:'Baby-making' 2Health News:Response rate high for some patients with metastatic melanoma treated with vemurafenib 2Health News:CDC Launches Graphic Anti-Smoking Campaign 2Health News:CDC Launches Graphic Anti-Smoking Campaign 3Health News:Art improves stroke survivors' quality of life 2
... 2.0 is a reagent and probe system ... The high throughput plate based system is ... provides a unique approach for RNA detection ... using branched DNA (bDNA) technology. Branched DNA ...
Cormet Hip Resurfacing is a conservative treatment for the young, active, high demand patient group which conserves femoral bone, provides anatomical bone loading, eliminates polyethylene and is desi...
QC 123 is an assayed quality control material for blood gas instrumentation. It is available in three (3) levels for monitoring analyzer performance at varying points within the clinical range....
...
Medicine Products: